<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Durant A</submitter><funding>H. Lundbeck A/S</funding><funding>Lumosity</funding><funding>NIA NIH HHS</funding><funding>the National Institute on Aging</funding><funding>Alzheimer's Drug Discovery Foundation</funding><funding>Cogstate</funding><funding>National Institutes of Health</funding><funding>Alzheimer&amp;apos;s Association</funding><funding>National Institute on Aging</funding><funding>Eli Lilly and Company</funding><funding>Laboratory for Neuro Imaging</funding><funding>the Wisconsin Registry for Alzheimer's Prevention</funding><funding>Novartis Pharmaceuticals Corporation</funding><funding>EuroImmun</funding><funding>Northern California Institute for Research and Education</funding><funding>NINDS NIH HHS</funding><funding>Meso Scale Diagnostics, LLC.</funding><funding>Araclon Biotech</funding><funding>Servier</funding><funding>Alzheimer's Association</funding><funding>NIH HHS</funding><funding>Bristol-Myers Squibb</funding><funding>F. Hoffmann-La Roche Ltd.</funding><funding>Alzheimer's Therapeutic Research Institute</funding><funding>Janssen Alzheimer Immunotherapy Research &amp; Development, LLC.</funding><funding>Elan Pharmaceuticals, Inc.</funding><funding>Bristol-Myers Squibb Company</funding><funding>the Alzheimer's Disease Neuroimaging Initiative</funding><funding>the National Institute of Biomedical Imaging and Bioengineering</funding><funding>Genentech, Inc.</funding><funding>Genentech</funding><funding>F. Hoffmann-La Roche</funding><funding>Pfizer Inc.</funding><funding>Illinois Department of Public Health</funding><funding>IXICO Ltd.</funding><funding>GE Healthcare</funding><funding>Canadian Institutes of Health Research</funding><funding>CereSpir, Inc.</funding><funding>Fujirebio</funding><funding>Transition Therapeutics</funding><funding>Takeda Pharmaceutical Company</funding><funding>Alzheimer&amp;apos;s Drug Discovery Foundation</funding><funding>BioClinica</funding><funding>Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC</funding><funding>Pfizer</funding><funding>following: AbbVie</funding><funding>University of Southern California</funding><funding>Neurotrack Technologies</funding><funding>BioClinica, Inc.</funding><funding>CIHR</funding><funding>Piramal Imaging</funding><funding>NeuroRx Research</funding><funding>The ADSP Phenotype Harmonization Consortium</funding><funding>Fujirebio US</funding><funding>Biogen</funding><funding>Lundbeck</funding><pagination>e71024</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12809718</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>22(1)</volume><pubmed_abstract>&lt;h4>Introduction&lt;/h4>"SuperAgers" are oldest-old adults (ages 80+) whose memory performance more closely resembles middle-aged adults. The present study examined apolipoprotein E (APOE) allele frequency in non-Hispanic Black (NHB) and non-Hispanic White (NHW) SuperAgers compared to controls and Alzheimer's disease dementia cases.&lt;h4>Methods&lt;/h4>In 18,080 participants from eight cohorts, harmonized clinical diagnostics and memory, executive function, and language domain scores were used to identify SuperAgers, cases, and controls across age-defined bins.&lt;h4>Results&lt;/h4>NHW SuperAgers had significantly lower frequency of APOE-ε4 alleles and higher frequency of APOE-ε2 alleles compared to all cases and controls, including oldest-old controls. Similar patterns were found in a small yet substan</pubmed_abstract><journal>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</journal><pubmed_title>Evaluating the association of apolipoprotein E genotype and cognitive resilience in SuperAgers.</pubmed_title><pmcid>PMC12809718</pmcid><funding_grant_id>R01 AG054047</funding_grant_id><funding_grant_id>R01 AG059716</funding_grant_id><funding_grant_id>K24 AG046373</funding_grant_id><funding_grant_id>R01 AG056405</funding_grant_id><funding_grant_id>R01 AG15819</funding_grant_id><funding_grant_id>U19 AG066567</funding_grant_id><funding_grant_id>UH2 NS100599</funding_grant_id><funding_grant_id>R01 AG037639</funding_grant_id><funding_grant_id>K01 AG073584</funding_grant_id><funding_grant_id>R01 AG0271761</funding_grant_id><funding_grant_id>U01 AG068057</funding_grant_id><funding_grant_id>W81XWH-12-2-0012</funding_grant_id><funding_grant_id>P30 AG10161</funding_grant_id><funding_grant_id>P30 AG072975</funding_grant_id><funding_grant_id>R01 AG064233</funding_grant_id><funding_grant_id>U24 AG074855</funding_grant_id><funding_grant_id>R01 AG022018</funding_grant_id><funding_grant_id>R01 AG067482</funding_grant_id><funding_grant_id>U24 AG072122</funding_grant_id><funding_grant_id>R01 AG021155</funding_grant_id><funding_grant_id>U01 AG024904</funding_grant_id><funding_grant_id>R01 AG017917</funding_grant_id><funding_grant_id>UH3 NS100599</funding_grant_id><pubmed_authors>Mez J</pubmed_authors><pubmed_authors>Barnes LL</pubmed_authors><pubmed_authors>Scollard P</pubmed_authors><pubmed_authors>Jefferson AL</pubmed_authors><pubmed_authors>Martin ER</pubmed_authors><pubmed_authors>Naj AC</pubmed_authors><pubmed_authors>Kukull WA</pubmed_authors><pubmed_authors>Haines JL</pubmed_authors><pubmed_authors>Cuccaro ML</pubmed_authors><pubmed_authors>Pericak-Vance MA</pubmed_authors><pubmed_authors>Gaynor LS</pubmed_authors><pubmed_authors>Johnson SC</pubmed_authors><pubmed_authors>Klinedinst BS</pubmed_authors><pubmed_authors>Farrer LA</pubmed_authors><pubmed_authors>Durant A</pubmed_authors><pubmed_authors>Alzheimer's Disease Neuroimaging Initiative (ADNI)*Alzheimer's Disease Genetics Consortium (ADGC)The Alzheimer's Disease Sequencing Project (ADSP)</pubmed_authors><pubmed_authors>Vardarajan BN</pubmed_authors><pubmed_authors>Saykin AJ</pubmed_authors><pubmed_authors>Albert MS</pubmed_authors><pubmed_authors>Dumitrescu L</pubmed_authors><pubmed_authors>Mayeux R</pubmed_authors><pubmed_authors>Hassenstab J</pubmed_authors><pubmed_authors>Wang LS</pubmed_authors><pubmed_authors>Crane PK</pubmed_authors><pubmed_authors>Hohman TJ</pubmed_authors><pubmed_authors>Kunkle BW</pubmed_authors><pubmed_authors>Cruchaga C</pubmed_authors><pubmed_authors>Engelman CD</pubmed_authors><pubmed_authors>Archer DB</pubmed_authors><pubmed_authors>Bush WS</pubmed_authors><pubmed_authors>Bennett DA</pubmed_authors><pubmed_authors>Schneider JA</pubmed_authors><pubmed_authors>Choi SE</pubmed_authors><pubmed_authors>Gifford KA</pubmed_authors><pubmed_authors>Mukherjee S</pubmed_authors><pubmed_authors>Trittschuh EH</pubmed_authors><pubmed_authors>Thompson PM</pubmed_authors><pubmed_authors>Keene CD</pubmed_authors><pubmed_authors>Lee ML</pubmed_authors></additional><is_claimable>false</is_claimable><name>Evaluating the association of apolipoprotein E genotype and cognitive resilience in SuperAgers.</name><description>&lt;h4>Introduction&lt;/h4>"SuperAgers" are oldest-old adults (ages 80+) whose memory performance more closely resembles middle-aged adults. The present study examined apolipoprotein E (APOE) allele frequency in non-Hispanic Black (NHB) and non-Hispanic White (NHW) SuperAgers compared to controls and Alzheimer's disease dementia cases.&lt;h4>Methods&lt;/h4>In 18,080 participants from eight cohorts, harmonized clinical diagnostics and memory, executive function, and language domain scores were used to identify SuperAgers, cases, and controls across age-defined bins.&lt;h4>Results&lt;/h4>NHW SuperAgers had significantly lower frequency of APOE-ε4 alleles and higher frequency of APOE-ε2 alleles compared to all cases and controls, including oldest-old controls. Similar patterns were found in a small yet substan</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Jan</publication><modification>2026-06-06T14:40:22.419Z</modification><creation>2026-05-31T03:10:16.346Z</creation></dates><accession>S-EPMC12809718</accession><cross_references><pubmed>41542929</pubmed><doi>10.1002/alz.71024</doi></cross_references></HashMap>